Curis Q4 net income $19.4M on Erivedge gain; PIPE raises $20.2M initial

CURIS INC

FY2025 net loss $7.6M ($0.58/shr) vs $43.4M ($6.88/shr) in FY2024; Q4 net income $19.4M ($1.23/shr).
Sold Erivedge royalty assets for $2.5M upfront and liability release; recognized $27.2M non-cash gain in Q4.
Cash $5.1M at Dec 31; Jan 2026 PIPE raised $20.2M initial, up to $20.2M more from Series B warrants; runway into H2 2027.
Initiated Phase 2 CLL study of emavusertib + zanubrutinib; PCNSL trial: 100% ORR in BTKi-naïve (5/5) patients.
AML triplet study: 62.5% of patients (5/8) achieved MRD conversion to undetectable after adding emavusertib to aza-ven.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CURIS INC reported Fourth Quarter 2025 results: revenue $1.1 million, net income $19.4 million, EPS $1.23.

Period: Fourth Quarter 2025
Revenue: $1.1 million
Net income: $19.4 million
EPS: $1.23
Result: reported results

Exact text from the filing

for the years ended December 31, 2025 and 2024, respectively. Revenues are comprised of royalty revenues related to Genentech and Roche's net sales of Erivedge ® . Revenues were $1.1 million and $3.3 million for the fourth quarters of 2025 and 2024, respectively. As previously announced, on November 6, 2025, the Company sold to TPC Investments Royalty LLC, a limited

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CURIS INC reported Year ended December 31, 2025 results: revenue $9.4 million, net income $7.6 million, EPS $0.58.

Period: Year ended December 31, 2025
Revenue: $9.4 million
Net income: $7.6 million
EPS: $0.58
Result: reported results

Exact text from the filing

per share on both a basic and diluted basis as compared to a net loss of $9.6 million or $1.25 on both a basic and diluted basis for the same period in 2024. Revenues, net were $9.4 million and $10.9 million for the years ended December 31, 2025 and 2024, respectively. Revenues are comprised of royalty revenues related to Genentech and Roche's net sales of Erivedge

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

CURIS INC filing history →

Source: SEC EDGAR

accession 0001108205-26-000030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.